Diagnostic methods for determining susceptibility to convulsive conditions
CA 2399169 A1 · Owner: Weaver, Donald F. · Inventors: Weaver, Donald F.; Campbell, Allyson J.; Lyon, Angela P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention exploits the discovery that amounts of uracil and thymine, metabolites, especially .beta.-aminoisobutyric acid in various bodily fluids, especially urine are, correlated with the occurrence of epilepsy when compared to matched control subjects. Analytical and diagnostic protocols including a novel high performance liquid chromatography system, for use in the invention are disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 16, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 16, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 16, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.